1. What predicts cognitive decline in de novo Parkinson's disease?
- Author
-
Arnaldi D. 1, Campus C. 2, Ferrara M 1, Famà F. 1, Picco A. 1, De Carli F. 3, Accardo J. 1, Brugnolo A. 1, Sambuceti G. 4, Morbelli S. 4, Nobili F. 1, and 4
- Subjects
Dopamine transporter SPECT ,Parkinson's disease ,Neuropsychological tests ,Perfusion SPECT ,Cognitive decline - Abstract
Subtle cognitive impairment can be detected in early Parkinson's disease (PD). In a consecutive series of de novo, drug-naive PD patients, we applied stepwise regression analysis to assess which clinical, neuropsychological, and functional neuroimaging (dopamine transporter [DAT] and perfusion single photon emission computed tomography [SPECT]) characteristics at baseline was predictive of cognitive decline during an average follow-up time of about 4 years. Decline both in executive (R(2) = 0.54; p = 0.0001) and visuospatial (R(2) = 0.56; p = 0.0001) functions was predicted by the couple of Unified Parkinson's Disease Rating Scale (UPDRS)-III score and caudate dopamine transporter (DAT) uptake in the less affected hemisphere (LAH). Verbal memory and language decline was predicted instead by caudate DAT uptake and brain perfusion in a posterior parieto-temporal area of the less affected hemisphere (R(2) = 0.42; p = 0.0005). No significant effect was shown for age, baseline neuropsychological scores, and levodopa equivalent dose at follow-up. The combined use of clinical structured examination and brain functional assessment by means of dual single photon emission computed tomography imaging appears as a powerful approach to predict cognitive decline in de novo PD patients.
- Published
- 2012